HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Dermaline Skin-Bleaching Cream

This article was originally published in The Rose Sheet

Executive Summary

Dermaline Skin-Bleaching Cream: Recalled by Little Ferry, N.J.-based Castillo Distributor, FDA says in its Nov. 27 Enforcement Report. The Class III (no adverse health effects likely) recall was initiated because "FDA analysis found" that the cream did not contain hydroquinone, which is listed as the active ingredient on product labeling. The recall extends to 1,152 8 oz. jars, 1,008 2 oz. jars and 34,512 4 oz. jars distributed in New York and New Jersey. According to Castillo, "little or no product remained on market at time of recall initiation," the Enforcement Report states. Santo Domingo, Dominican Republic-based Leivon Cosmetics manufactures the Dermaline cream...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS003506

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel